Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Niravam Clear all
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 4 Interventional

Oral vs IV Sedation for Cataract Surgery in Older Adults

NCT07154147
View directory record Official record
Conditions
Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions
Alprazolam, Midazolam
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

NCT00865761
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

NCT00829426
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

NCT01256151
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Alprazolam tablet, Alprazolam sublingual
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Results available

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

NCT00662259
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Alprazolam (Xanax), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218
View directory record Official record
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions
Lasmiditan, Alprazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Effect of Rapastinel on Driving Performance

NCT03814733
View directory record Official record
Conditions
Driving Performance
Interventions
Rapastinel, Alprazolam, Ketamine, Rapastinel Matched Placebo, Alprazolam Matched Placebo, Ketamine Matched Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
21 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885
View directory record Official record
Conditions
Anxiety Disorders
Interventions
0.25 mg alprazolam, 1.0 mg alprazolam, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2014 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

NCT03948243
View directory record Official record
Conditions
Food-drug Interaction
Interventions
Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
View directory record Official record
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions

NCT01188057
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472
View directory record Official record
Conditions
Healthy
Interventions
4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 4, 2026, 4:08 PM EDT
Terminated Phase 4 Interventional

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

NCT00635531
View directory record Official record
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

NCT01188031
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Sep 4, 2026, 4:08 PM EDT
Completed No phase listed Observational

Alprazolam and Eating Behavior in Anorexia Nervosa

NCT01411813
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Not listed
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 4, 2026, 4:08 PM EDT
Recruiting Phase 2 Interventional

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

NCT05006079
View directory record Official record
Conditions
Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse
Interventions
Morphine, Alprazolam, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

NCT07777965
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users
Interventions
Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

NCT04782388
View directory record Official record
Conditions
Healthy Study Participants
Interventions
Alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Terminated Phase 4 Interventional

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

NCT00635076
View directory record Official record
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

NCT03398083
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
THC, Alprazolam, Placebo oral capsule, CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 4, 2026, 4:08 PM EDT